retatrutide clinical trial safety data Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Side Effects Research |

B.ModyM

Any therapies, consultations, or prescriptions are provided only following assessment by a licensed physician and where clinically appropriate

GLP-1 receptor agonists semaglutide (Ozempic/Wegovy), tirzepatide (Zepbound/Mounjaro) are genuinely impressive drugs

GLP-1 medications have changed the conversation around weight lossfor the better

VSMC phenotypic switching is characterized by transformation from a quiescent contractile to an activated synthetic phenotype, promoting proliferation and leading to the formation of the neointima, the pathological vascular compartment critical for the development of atherosclerosis